Health Canada-authorized trial to evaluate a single supervised dose of natural psilocybin, with dosing expected to be completed by the end of 2027

Up to 200 participants at sites across Canada, among the largest studies of naturally derived psilocybin to date

VANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) — Optimi Health Corp. (Nasdaq: OPTH) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announces plans to initiate a multisite Phase 2 clinical trial evaluating psilocybin-assisted therapy for individuals with major depressive disorder (“MDD“). The trial is planned to be initiated in the first half of 2027, with dosing expected to be complete by the end of 2027.

The Phase 2 clinical trial is authorized to proceed by Health Canada and will enroll up to 200 participants across multiple sites in Canada, evaluating the safety and efficacy of a single supervised dose of natural psilocybin in the treatment of MDD. The primary efficacy endpoint is the change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline, the most widely used clinician-rated measure of depressive symptom severity in trials of this kind.

“A 200-subject Phase 2 trial in major depressive disorder is the largest clinical commitment Optimi has made to date. We will supply our own naturally derived psilocybin, manufactured at our GMP facility, and we will have exclusive ownership of the trial results,” said Dane Stevens, Optimi Chief Executive Officer and Co-Founder. “As we broaden our strategy to include clinical drug development, this Phase 2 trial is an initial step toward potential registration. Few companies in this sector are commercial today while also advancing their own clinical development. In Canada, we already hold a Drug Establishment Licence and supply psilocybin through Health Canada’s Special Access Program. This trial builds directly on that foundation, and we can comfortably fund it with current cash on hand.”

The clinical trial is set to be one of the largest clinical studies of naturally derived psilocybin to date, and will include periodic interim safety and efficacy readouts, with full topline results available after dosing and follow-up evaluations are completed for all 200 participants.

MDD is among the most common mental health conditions worldwide, affecting an estimated 332 million people, according to the World Health Organization.1 A substantial proportion of patients do not respond adequately to existing antidepressant treatments, which typically require weeks of continuous use before clinical benefits emerge.

1World Health Organization, Depressive disorder (depression) fact sheet, 2025. Available at: https://www.who.int/news-room/fact-sheets/detail/depression

The safety and efficacy of psilocybin assisted therapy to treat MDD is still under investigation and none of Optimi’s psilocybin drug products received market authorization by Health Canada.

About Optimi Health Corp.

Optimi Health Corp. is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.

For more information, please visit optimi.net.

For more information, please contact:
Dane Stevens, CEO
Optimi Health Corp.
(778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca

Investor Relations Contact:
CORE IR
ir@optimi.net

Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws, including statements regarding the proposed clinical trial, the availability and enrolment of patients in the trial, the utilization of the data derived from the trial, and the ability to conduct evaluations as part of the trial, the Company’s ability to manufacture and ship products from its Canadian facility, and the Company’s positioning in the regulated psychedelic medicine market. Forward-looking statements and forward-looking information are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “estimates,” “may,” “will,” “would,” “could,” or similar expressions. Forward-looking statements and forward-looking information are based on several assumptions and are subject to a number of known and unknown risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include those described under “Risk Factors” in the Company’s registration statement on Form F-1, as amended, and other filings with the U.S. Securities and Exchange Commission made from time to time which are available at www.sec.gov and on SEDAR+ at www.sedarplus.ca and in the Company’s continuous disclosure filings available under its SEDAR+ profile at www.sedarplus.ca. These forward-looking statements reflect current expectations of management regarding future events and speak only as of the date of this press release. Except as expressly required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

VANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (the “Company or Cannabix”) developer of marijuana and alcohol breath testing technologies, is pleased to announce the deployment of its BreathLogix alcohol monitoring solution with the Lake County Community Corrections Program in Indiana. Lake County is Indiana’s second-most populous county, serving residents in the greater Chicago metropolitan region.

The BreathLogix system will support court-ordered alcohol monitoring initiatives administered by Lake County’s community corrections program staff. The deployment is designed to assist program administrators in monitoring participant compliance with court-imposed abstinence requirements while improving operational efficiency and reducing administrative burden.

Under the program, participants are required to undergo scheduled or random alcohol testing as a condition of probation, treatment, pre-trial release, or other court-supervised programs. The deployment is being facilitated by AlcoPro, Inc., an authorized reseller.

Under the program, participants may be required to undergo scheduled or random alcohol testing as a condition of probation, diversion, treatment, pre-trial release, or other court-supervised programs. BreathLogix enables participants to provide breath samples autonomously while maintaining identity verification through integrated photo capture technology.

BreathLogix rapidly screens for alcohol using a breath sample while simultaneously capturing a photograph of the user for identity verification. The system provides precise Blood Alcohol Content (BAC / BrAC) readings and can automatically deliver real-time alerts via SMS and email to designated program administrators when positive results are detected.

The deployment further expands Cannabix’s presence within the U.S. corrections, probation, treatment, and public safety markets where organizations are seeking automated alcohol testing solutions that improve compliance oversight while reducing staffing requirements.

BreathLogix Alcohol device available with for County Sobriety Programs

Figure 1. BreathLogix Alcohol device available with for County Sobriety Programs

BreathLogix supports a broad range of alcohol monitoring applications, including:

  • Court-ordered alcohol monitoring
  • Probation and parole programs
  • Pre-trial release supervision
  • Diversion and specialty court programs
  • Treatment and recovery programs
  • Random and scheduled alcohol testing
  • Workplace and safety-sensitive screening
  • Return-to-work and fitness-for-duty assessments

By enabling frequent, reliable and automated alcohol screening, BreathLogix helps courts, treatment providers and supervision agencies strengthen compliance monitoring, improve participant accountability and enhance public safety outcomes.

Marketing Agreement

The Company has entered into a marketing services agreement (the “Agreement”) with Outside the Box Capital Inc. (“OTBC”), an arm’s-length marketing firm based in Oakville, Ontario. Pursuant to the Agreement, OTBC will provide marketing services, including social media marketing, content planning and creation, and the production and distribution of feature content regarding the Company through OTBC’s proprietary media channels and selected third-party platforms. The Agreement is effective September 9, 2026, for a term of six months. In consideration for the services to be provided under the Agreement, the Company has agreed to pay OTBC a one-time cash fee of $150,000 plus applicable taxes and 335,000 stock options (the “Options”) to acquire common shares of the Company at an exercise price of $0.45 per share for a period of one year from the date of grant. The Options will vest in accordance with the policies of the Canadian Securities Exchange and the Company’s equity incentive plan. Any common shares issued upon the exercise of the Options will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws.

OTBC is controlled by Jason Coles. OTBC and Mr. Coles are arm’s-length parties to the Company. Other than the Options described above, neither OTBC nor Mr. Coles currently holds any direct or indirect interest in the Company or its securities. OTBC has no relationship with the Company other than pursuant to the Agreement described in this news release.

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leading developer of breath-based technologies designed to enhance public safety and reduce impairment-related risks in a range of different settings. The Marijuana Breath Test (MBT) targets delta-9 THC—the primary psychoactive compound in cannabis—in breath, providing a practical solution for identifying recent marijuana use.

The BreathLogix, unmanned alcohol screening solution supports organizations in proactively monitoring alcohol impairment, strengthening safety protocols, and promoting responsible behavior. By delivering innovative, non-invasive screening tools, Cannabix aims to help reduce accidents, improve decision-making, and protect organizations, individuals and the public at large. Visit www.cannabixtechnologies.com

We seek Safe Harbor.
On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains certain “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements are often identified by words such as “expects,” “anticipates,” “believes,” “intends,” “plans,” “may,” “will,” “could,” “should,” “potential,” and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements regarding: the anticipated benefits, performance and adoption of the Company’s BreathLogix alcohol monitoring system; the expected use of the system by community corrections agencies and other public sector organizations; the Company’s ability to expand deployments of BreathLogix in the United States and other jurisdictions; the commercialization and market acceptance of the Company’s products and technologies; the Company’s ability to enter into additional customer, distribution, service, or strategic partnership agreements; and the Company’s ongoing business, product development and financing plans. Forward-looking statements are based on management’s current expectations, assumptions and beliefs and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Such factors include, without limitation: the ability of the Company to successfully deploy and support its technologies; customer adoption and retention; regulatory developments; changes in government procurement practices or community corrections requirements; competitive developments; technological advancements by competitors; economic and market conditions; the availability of financing; and other risks detailed from time to time in the Company’s public disclosure documents. There can be no assurance that the Company’s products will achieve commercial acceptance, that existing deployments will lead to additional contracts or revenue opportunities, or that any anticipated business objectives, strategic initiatives, partnerships, or growth opportunities will be realized. Actual results may differ materially from those currently anticipated in such forward-looking statements. The forward-looking statements contained in this news release are made as of the date hereof and are based on the beliefs, estimates, expectations and opinions of management on the date such statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c280215e-c351-42df-b85c-5f581f46994e

 

Bank of Åland Plc
Stock exchange release
September 10, 2026, 15.45 EEST

Bank of Åland Plc to increase prime rate

The Bank of Åland Plc (Ålandsbanken Abp) has decided to increase its prime rate by 0.25 percentage points, from 2.25 per cent to 2.50 per cent. The basis for this decision is rising market interest rates. The change goes into effect on September 24, 2026.

Bank of Åland Plc

For further information, please contact:
Peter Wiklöf, Managing Director and Chief Executive, Bank of Åland Plc, tel +358 40 512 7505

Company will hold a formal presentation and one-on-one investor meetings September 14-16, 2026

MBody AI

ISFIYA, Israel and LAS VEGAS, Sept. 10, 2026 (GLOBE NEWSWIRE) — MBody AI Ltd. (“MBody AI” or the “Company”) (NASDAQ: MBAI) today announced that John Fowler, Chief Executive Officer and Tim Hayden, Chief Financial Officer of MBody AI, will present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, at the Lotte New York Palace Hotel in New York City.

In addition to the formal presentation which will be available On-Demand, management will be available for one-on-one investor meetings during the conference. Investors interested in scheduling a one-on-one meeting with management during the conference should contact their H.C. Wainwright representative or meetings@hcwco.com or Lytham Partners at 602-889-9700 or ir@mbody.ai.

MBody AI’s Orchestrator is a proprietary, hardware-agnostic software platform that serves as an intelligence layer designed to enable autonomous systems to operate, coordinate, and improve more effectively than they otherwise would in real-world physical environments. It is designed as a full-stack embodied AI software system that integrates multiple functional components intended to support autonomous operation and fleet-level coordination.

The two core features of Orchestrator are AI Optimization, Task Verification and Reporting. AI Optimization uses artificial intelligence to assess telemetry and run-time data and generate recommendations to improve performance against customer key performance indicators, across a customer’s fleet regardless of brand.

Task Verification and Reporting provides unified dashboarding and reporting across a customer’s full fleet and multiple robot types, including verification that assigned tasks have been completed.

Learn more about MBody AI’s growth trajectory at ir.mbody.ai

About H.C. Wainwright & Co.

H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory, sales & trading, research, and related services to public and private growth companies across multiple focuses and regions. The HCW team has been the leader in the CMPO (confidentially marketed public offerings), RD (registered direct offering) and PIPE (private investment in public equity) transaction markets since 1998.

About MBody AI Ltd.

MBody AI Ltd. (NASDAQ: MBAI) develops enterprise software that deploys and manages autonomous robot workforces for hospitality and gaming operators. The Company’s proprietary MBody AI Orchestrator is a hardware-agnostic software platform that manages diverse robot fleets from multiple vendors across sites and use cases under long-term agreements. MBody AI counts Fortune 500 operators among its customers.

No Offer or Solicitation

This press release does not constitute an offer to sell or a solicitation of an offer to buy, and shall not constitute an offer, solicitation, or sale in any state, province, territory, or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements made in graphics, images, headlines, and other visual elements of this release. All statements other than statements of historical fact are forward-looking statements, which include, among others, statements regarding the expected performance, functionality, and capabilities of the MBody AI Orchestrator platform; the Company’s technology roadmap; the Company’s expectation that operational data generated by its deployments will refine its models and improve platform performance over time; the Company’s deployment pipeline, customer expansion, and commercial scaling; the anticipated growth of the embodied AI market; the Company’s ability to maintain continued compliance with Nasdaq listing requirements; and the Company’s continued qualification as a foreign private issuer. These forward-looking statements are based on the Company’s current intentions, beliefs, and expectations regarding future events. Actual results may differ materially due to risks and uncertainties including, but not limited to, the risk that the multi-brand fleet control capability does not complete testing or is not deployed with customers on the anticipated timeline or at all; the risk that the customer-systems integration capability is never completed or made available, and that the related provisional patent applications do not result in issued patents; the risk that the platform does not perform as designed or that operational data does not yield the expected improvements; customer concentration risk, the Company being substantially dependent on two enterprise customers; the Company’s ability to convert pilot deployments into contracted revenue; the risk that the Company fails to satisfy Nasdaq continued listing standards, including the minimum bid price and shareholders’ equity requirements; the risk that the Company ceases to qualify as a foreign private issuer and becomes subject to domestic reporting requirements; the Company’s need for additional capital and the dilutive effect of any financing; market conditions; and other factors described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by law.

Quick Facts

Issuer: MBody AI Ltd. (NASDAQ: MBAI)
Listing: Nasdaq Capital Markets
Sector: Technology
Industry: Embodied AI and enterprise robotics (physical AI)
Event: H.C. Wainwright 28th Annual Global Investment Conference
Date: September 14-16, 2026
Location: Lotte New York Palace Hotel, New York City
CUSIP M6S83C106

Investor Relations:
Lytham Partners, LLC
602-889-9700
ir@mbody.ai

Media Contact:
Core IR
ir@mbody.ai

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1633c2e1-2003-4789-b023-5900f7374b46

DENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, Chief Executive Officer of SeaStar Medical, will participate in the upcoming HC Wainwright 28th Annual Global Investment Conference being held September 14 to 16, 2026 in New York City.

The SeaStar Medical presentation will be available on September 11, 2026, at 7:00 am Eastern Time and can be accessed by visiting the Events & Presentations page, located under the Investor Relations section of the SeaStar Medical website. The presentation will be available for 60 days following the event.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Contact:
IR@SEASTARMED.COM

Management to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth Conference and the H.C. Wainwright 28th Annual Global Investment Conference in September 2026

CORSICANA, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) — Birchtech Corp. (NYSE American: BCHT) (TSX: BCHT) (“Birchtech” or the “Company”), a leader in specialty activated carbon technologies for sustainable air and water treatment, today announced that management will participate in two upcoming investor conferences: Lake Street Capital Markets’ 10th Annual Best Ideas Growth Conference and the H.C. Wainwright 28th Annual Global Investment Conference.

Richard MacPherson, President and CEO of Birchtech, is scheduled to host one-on-one meetings with institutional investors at each event, and will deliver a corporate presentation at the H.C. Wainwright conference, as follows:

Lake Street Capital Markets’ 10th Annual Best Ideas Growth Conference
Conference Date: September 10, 2026
Location: The Metropolitan Club, New York, NY
Format: 1×1 Meetings Only

H.C. Wainwright 28th Annual Global Investment Conference
Conference Dates: September 14-16, 2026
Location: Lotte New York Palace Hotel, New York, NY
Format: Presentation & 1×1 Meetings
Presentation Date: September 14, 2026
Presentation Time: 1:00 PM Eastern Time
Webcast: https://journey.ct.events/view/06c774a5-563e-4cc8-b69e-5ae9d31b6e7c

A live audio webcast and archive of the H.C. Wainwright presentation will be available using the webcast link above. For more information or to schedule a meeting with management, please contact MZ Group at BCHT@mzgroup.us.

About Birchtech Corp.

Birchtech Corp. (NYSE American: BCHT) (TSX: BCHT) is a leader in specialty activated carbon technologies delivering innovative solutions for air and water purification to support a cleaner, more sustainable future. The Company provides patented SEA® sorbent technologies for mercury emissions capture for the coal-fired utility sector and SEA disruptive water purification technologies with a specialization on removing contaminants, including ‘forever chemicals’ such as PFAS, from potable water and industrial wastewater. Backed by a strong intellectual property portfolio and a team of activated carbon experts, Birchtech provides cleaner air to North American communities and is applying this expertise to a novel approach in water purification. To learn more, please visit www.birchtech.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain “forward-looking statements” that are made pursuant to the Safe Harbor Provisions of the U.S. Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are generally identified by using words such as “anticipate,” “believe,” “plan,” “expect,” “intend,” “will,” and similar expressions, but these words are not the exclusive means of identifying forward-looking statements. Forward-looking statements in this release include statements relating to expected developments and growth in Birchtech’s business, as well as anticipated investor engagements and the Company’s participation in investor conferences. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. In addition, this release contains time-sensitive information that reflects management’s best analysis only as of the date of this release. Birchtech does not undertake any obligation to publicly update or revise any forward-looking statements to reflect future events, information or circumstances that arise after the date of this release. Further information concerning issues that could materially affect financial performance or other forward-looking statements contained in this release can be found in Birchtech’s periodic filings with the Securities and Exchange Commission or Canadian securities regulators.

Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group – MZ North America
(949) 259-4987
BCHT@mzgroup.us
www.mzgroup.us

CULVER CITY, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games”), a leading independent global developer and publisher of interactive digital entertainment, today announced it will be presenting and holding one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is being held on September 14-16, 2026, at the Lotte New York Palace Hotel, New York City.

Snail Games’ management is scheduled to present on Monday, September 14, 2026, at 4:00 p.m. Eastern time. Snail Games’ management will also be available for one-on-one meetings during the conference. 

The presentation will be available for viewing online via webcast here.

About Snail, Inc.
Snail, Inc. (Nasdaq: SNAL) is a leading global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs, and mobile devices. For more information, please visit: https://snail.com/.

About H.C. Wainwright & Co.
H.C. Wainwright is a full‐service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors.
For more information visit H.C. Wainwright & Co. at www.hcwco.com.

Snail, Inc. Investor Relations:
Gateway Group, Inc.
John Yi and Steven Shinmachi
949-574-3860
SNAL@gateway-grp.com

Gen-Tracker’s universal, automatic transfer switch (ATS)-based monitoring technology and veteran team extend OmniMetrix’s reach to standby generators of virtually any make, model or age

OAKDALE, Minn. and BUFORD, Ga., Sept. 10, 2026 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (Nasdaq: ACFN), a provider of remote monitoring and control solutions for critical infrastructure, today announced that its OmniMetrix subsidiary has acquired substantially all of the assets of Generator Solutions, Inc., a provider of remote monitoring systems for standby generators under the “Gen-Tracker” brand name, effective September 9, 2026.

Generator Solutions is one of the longest-standing independent generator monitoring providers, with approximately $1.1M in recurring annual monitoring revenue and $400,000 in annual monitoring equipment sales. Since its founding in St. Paul, Minnesota in 2001, Generator Solutions has established Gen-Tracker as one of the most respected monitoring platforms in the commercial and industrial standby generator market.

Agreement Terms
Pursuant to the asset purchase agreement, OmniMetrix paid $1.0M in cash at closing and agreed to make additional cash payments of $450,000 per year, for each of the next four years, and a final payment of $700,000 in the fifth year, for total consideration of $3.5M. Acquired assets include the company’s customer accounts, dealer relationships, trade names, trademarks, technology, accounts receivables and hardware inventory.

Every full-time Generator Solutions employee has joined OmniMetrix and will continue to work from the existing Minnesota location. The team brings decades of combined, hands-on experience in standby power, automatic transfer switch (ATS) integration and generator dealer support.

Two Complementary Approaches, One Provider
Generator Solutions has historically competed with OmniMetrix in the commercial and industrial standby generator monitoring market, and its flagship Gen-Tracker product takes a fundamentally different path to the same goal. Rather than connecting to the generator’s engine controller, Gen-Tracker monitors generator readiness through the ATS –– a design that works across generators of virtually any make, model, or age, including the large installed base of older units that predate modern controllers.

Combined with OmniMetrix’s controller-level, enterprise-grade platform, the two approaches give dealers and end customers a single source for:

  • Deep diagnostics on modern, controller-equipped generators
  • Universal readiness monitoring on legacy, orphaned and mixed-brand fleets
  • One provider and one support organization for a facility portfolio, regardless of what’s behind the door

CEO Commentary
Acorn and OmniMetrix CEO, Jan Loeb, commented, “Gen-Tracker is a proven, first-class solution that builds on our capabilities and market leadership, while extending our service reach. By combining our controller-level and enterprise-grade monitoring with Gen-Tracker’s ATS-based universal monitoring approach, we can now serve a broader range of customers and generator environments than either company could alone.

“Importantly, we’re adding a team that has spent 25 years in this market, bringing deep expertise in transfer switches, field installation, and dealer support to make OmniMetrix an even stronger partner to every customer we serve.

“Based on OmniMetrix’s first half monitoring revenue of $2.8M, we expect the acquisition to increase annualized monitoring revenue by at least 15%. We also expect the transaction to be accretive to our 2027 net income by at least $0.10 per diluted share.

“After an extended process of dialogue and evaluation, we are excited to welcome the Gen-Tracker operations to the OmniMetrix family, and we look forward to leveraging our collective strengths to drive continued growth across the business.”

About Acorn (www.acornenergy.com) and OmniMetrixTM (www.omnimetrix.net)
Acorn’s wholly-owned OmniMetrix subsidiary is a pioneer and leader in wireless remote monitoring and control solutions for standby generators, gas pipelines, and other infrastructure assets. Its recently-launched OMNI360 product line provides cutting-edge infrastructure management and security solutions for cell towers, data centers and utility networks. OmniMetrix serves tens of thousands of commercial and residential endpoints, including over 25 Fortune/Global 500 companies in sectors including telecom, manufacturing, healthcare, data centers, retail, public transportation, energy distribution and government facilities, as well as residential customers through generator dealers.

OmniMetrix’s industry-leading, cost-effective solutions make critical systems more reliable, provide security, and also enable automated “demand response” electric grid support via enrolled backup generators.

Safe Harbor Statement
This press release includes forward-looking statements, which are subject to risks and uncertainties. There are no assurances that Acorn will be successful in growing its business, increasing its revenue, increasing profitability, or maximizing the value of its operating company and other assets. A complete discussion of the risks and uncertainties that may affect Acorn Energy’s business, including the business of its subsidiary, is included in “Risk Factors” in the Company’s most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.

Follow us

X (formerly Twitter):
StockTwits:                   
@Acorn_IR and @OmniMetrix
@Acorn_Energy


Investor Relations Contacts
Catalyst IR
William Jones, 267-987-2082
David Collins, 212-924-9800
acfn@catalyst-ir.com

SORA-based authorization for ZenaDrone enables the Drone as a Service platform to deliver large-scale precision agriculture applications to farmers and supports planned expansion into additional European markets

VANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech” or the “Company”), a technology company specializing in AI drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces that its Drone as a Service subsidiary will expand its precision agriculture drone-based services to farmers in Ireland. The Company received Specific Operations Risk Assessment (SORA) approval from the Irish Aviation Authority (IAA), granted under European Union Aviation Safety Agency (EASA) guidelines. The approval was given to its drone subsidiary, ZenaDrone, at the Company’s EMEA DaaS headquarters located near Dublin, Ireland, authorizing large-scale targeted aerial application of fertilizer, lime, bio stimulants, and other non-plant protection products on Irish farmland and granular spreading at scale, helping farmers reduce product inputs, operating costs, risk to personnel, and environmental impact.

“This milestone for ZenaDrone and our Drone as a Service platform demonstrate that we can clear the regulatory bar for the initiation of large-scale aerial precision agriculture in Ireland and beyond,” said Shaun Passley, Ph.D., CEO of ZenaTech. “EASA’s framework is used across the European Union, as this approval provides a replicable template to apply market by market rather than starting fresh. We believe that precision agriculture is a large and underpenetrated opportunity globally, and having an approved and repeatable path forward will aid our roll out and recurring Drone as a Service revenue growth as we plan future expansion across Europe and into other regions.”

Precision agriculture is a sector facing historically high fertilizer costs and increasing environmental scrutiny. Drone-based aerial application allows precise, targeted spreading on terrain unsuitable for heavy machinery, reducing soil compaction and run-off risk while cutting input costs and personnel exposure. Ireland’s Environmental Protection Agency reported in 2026 that nitrogen concentrations in Irish rivers rose 10% year-over-year, with excess fertilizer run-off cited as a leading cause, underscoring demand for more precise application methods of the kind that ZenaTech’s ZenaDrone and DaaS platform are now authorized to provide.

The SORA authorization allows the company to operate complex, autonomous aerial missions at scale, without requiring customers to navigate aviation safety regulation, pilot certification, hardware costs and maintenance directly. Management believes this regulatory pathway supports its broader strategy of scaling DaaS as a recurring-revenue, subscription-based service across multiple geographies and industry verticals, including forestry, renewables, construction, and infrastructure monitoring.

About ZenaTech

ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for applications such as agriculture and logistics, as well as ISR, cargo, and counter-UAS for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives.

About ZenaDrone

ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio under development includes the ZenaDrone 1000 for ISR defense and specialized cargo, the IQ Nano for indoor inventory management and security, the IQ Square for outdoor inspections and maintenance, the IQ Quad for land surveying, the IQ Aqua, for underwater applications, and the IQ Octo for precision agriculture. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system.

Contacts for more information:

Company, Investors, and Media:

Linda Montgomery

ZenaTech

312-241-1415

Investors:

Michael Mason

CORE IR

investors@zenatech.com

Safe Harbor

This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities, including its planned franchise business strategy for drone-based power washing described above, which is in the planning stage and subject to change. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. Forward-looking information in this document includes, but is not limited to, ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; its ability to develop and finalize a franchise business strategy and operations manual for drone-based power washing services and to execute on that strategy in Florida and nationally as currently contemplated; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated, including its drone products such as the ZenaDrone 1000, IQ Square, and IQ Nano; ZenaTech’s ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and its needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions or franchise agreements; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks and uncertainties disclosed under the heading “Risk Factors” in the Company’s Form F-1, Form 20-F and other filings filed with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at www.sec.gov. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

TEL-AVIV, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) — Hub Cyber Security Ltd. (Nasdaq: HUBC) (“HUB Security” or the “Company”), a global provider of confidential computing and secured data fabric technologies, today announced a 1-for-25 reverse share split of its ordinary shares, no par value per share (the “Ordinary Shares”). The reverse share split and corresponding share capital adjustment will become effective at 11:59 p.m. Eastern Time on Friday, September 11, 2026. The Ordinary Shares will begin trading on a split-adjusted basis on The Nasdaq Stock Market LLC (“Nasdaq”) at the open of business on Monday, September 14, 2026, under the existing trading symbol “HUBC,” but the Ordinary Shares will trade under a new CUSIP number, M6000J309. HUB Security’s outstanding warrants will continue to be traded under the symbols “HUBCW” and “HUBCZ” and the CUSIP numbers for such warrants will remain unchanged.

As a result of the reverse share split, every 25 issued and outstanding Ordinary Shares will automatically be converted into one Ordinary Share. No fractional shares will be issued as a result of the reverse share split. Instead, all fractional shares will be rounded down to the nearest whole share. The reverse share split affects all shareholders uniformly and will not alter any shareholder’s percentage ownership interest in the Company’s issued and outstanding Ordinary Shares, except for adjustments that may result from the treatment of fractional shares. As of the date hereof, the Company had 44,895,531 Ordinary Shares issued and outstanding, which, following the effectiveness of the reverse share split, will result in 1,795,821 Ordinary Shares outstanding on a post-split basis (taking into effect the settlement of fractional shares).

The reverse share split will also affect the Company’s derivative securities, including outstanding notes, options, warrants and restricted share units (collectively, the “Outstanding Equity Rights”). Generally, the plans and other documents pertaining to the Outstanding Equity Rights include provisions providing for adjustments in the event of a reverse share split in order to maintain the same economic effect. Specifically, the exercise price and the number of Ordinary Shares issuable pursuant to Outstanding Equity Rights will be adjusted pursuant to the terms of such instruments in connection with the reverse share split.

The Company believes the reverse share split will increase the per share trading price of the Ordinary Shares and enable the Company to maintain compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450(a)(1).

Additional information regarding the reverse share split can be found in the Company’s proxy statement furnished to the Securities and Exchange Commission on August 4, 2026.

For further information or inquiries, please contact: info@hubsecurity.com

About HUB Security Ltd.

HUB Cyber Security Ltd. (Nasdaq: HUBC) has operated in confidential computing, AI-driven data fabric, and cybersecurity. HUB’s Secured Data Fabric has historically empowered organizations to virtualize, secure, and analyze sensitive data across borders and silos generating real-time intelligence while meeting the highest regulatory standards. HUB is currently implementing a comprehensive restructuring, during which its Board of Directors and management team have taken steps to improve liquidity, simplify the Company’s organizational structure, cut operating costs and strengthen corporate governance. The Board of Directors continues to explore various strategic alternatives intended to maximize value for shareholders and position HUB for future growth.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “future,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “seem,” “should,” “will,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements are based on the current expectations of the management of HUB Security, as applicable, and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties, or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those discussed and identified in public filings made with the SEC by the HUB Security and the following: (i) significant uncertainty regarding the adequacy of HUB’s liquidity and capital resources and its ability to repay its obligations as they become due; (ii) the war between Israel and Hamas commenced in October 2023, which may harm Israel’s economy and HUB’s business; (iii) expectations regarding HUB’s strategies and future financial performance, including its future business plans or objectives, prospective performance and opportunities and competitors, revenues, products and services, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures, and HUB’s ability to invest in growth initiatives and pursue acquisition opportunities; (iv) the outcome of any legal or regulatory proceedings against HUB in connection with our previously announced internal investigation or otherwise; (v) the ability to meet stock exchange continued listing standards and remain listed on the Nasdaq; (vi) competition, the ability of HUB to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (vii) limited liquidity and trading of HUB’s securities; (viii) geopolitical risk, including military action and related sanctions, and changes in applicable laws or regulations; (ix) the possibility that HUB may be adversely affected by other economic, business, and/or competitive factors; and (x) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in HUB’s Annual Report on Form 20-F filed on July 17, 2026. Should one or more of these risks or uncertainties materialize or should any of the assumptions made by the management of HUB prove incorrect, actual results may vary in material respects from those expressed or implied in these forward-looking statements.

Should one or more of these risks or uncertainties materialize, or should any of the assumptions made by the management of HUB Security prove incorrect, actual results may vary in material respects from those expressed or implied in these forward-looking statements.

All subsequent written and oral forward-looking statements concerning the business combination or other matters addressed in this press release and attributable to HUB Security or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in the press release. Except to the extent required by applicable law or regulation, HUB Security undertakes no obligation to update these forward-looking statements to reflect events or circumstances after the date of this press release to reflect the occurrence of unanticipated events.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.